US5212162A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
Assignee: Alcon Research LLC
•
Filing: 1992-03-25
•
Granted: 1993-05-18
•
Expires: 2012-03-25
Abstract
Abstract Ophthalmic compositions comprising combinations of gelling polysaccharides and finely-divided drug carrier substrates which become relatively more viscous on contact with the eye are disclosed. These ophthalmic compositions are both comfortable and long-lasting Ophthalmic compositions further comprising a pharmaceutically active drug are also disclosed, as are methods of use.
Inventors
- 👤 Paul J. T. Missel
- 👤 John C. Lang
- 👤 Rajni Jani
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 21:28
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0048; A61K47/00; A61K47/50; A61K47/51; A61K47/56; A61K47/58; A61K47/585; A61K47/61
Claims Analysis
Total Claims: 29
Claim 1
Independent Claim
37 words
A topical ophthalmic composition comprising a gelling polysaccharide and a finely-divided drug carrier substrate, wherein the concentration of said gelling polysaccharide allows the composition to be administrable as a drop which gels upon instillation to the eye.
Claim 2
Dependent Claim
37 words
A topical ophthalmic composition comprising a gelling polysaccharide and a finely-divided drug carrier substrate, wherein the concentration of said gelling polysaccharide allows the composition to be administrable as a drop which gels upon instillation to the eye.
Claim 3
Dependent Claim
16 words
The composition of claim 1 wherein the finely-divided drug carrier substrate is an ion exchange resin.
Claim 4
Dependent Claim
33 words
The composition of claim 1 wherein the gelling polysaccharide concentration is between 0.1% and 3.0% by weight/volume and the concentration of the finely-divided drug carrier substrate is between 0.05% and 10.0% by weight/volume.
Claim 5
Dependent Claim
25 words
The composition of claim 1 wherein the gelling polysaccharide is selected from the group consisting of xanthan gum, locust beam gum, gellan gum, and carrageenan.
Claim 6
Dependent Claim
12 words
The composition of claim 4 wherein the gelling polysaccharide is gellan gum.
Claim 7
Dependent Claim
23 words
The composition of claim 4 wherein the gelling polysaccharide is a carrageenan having not more than 1.0 sulfate moiety per disaccharide repeating unit.
Claim 8
Dependent Claim
11 words
The composition of claim 6 wherein said carrageenan is eucheuma carrageenan.
Claim 9
Dependent Claim
10 words
The composition of claim 6 wherein said carrageenan is furcellaran.
Claim 10
Dependent Claim
25 words
The composition of claim 1 wherein the pre-dosed viscosity thereof is between 1 and 500 cps and the post-dosed viscosity is greater than 50 cps.
Claim 11
Dependent Claim
34 words
The composition of claim 1 wherein the pre-dosed viscosity thereof is between 1 and 500 cps and the post-dosed gel has a modulus of elasticity between 1×10 4 and 5×10 5 dynes/cm 2 .
Claim 12
Dependent Claim
38 words
The composition of claim 1 wherein the pre-dosed modulus of elasticity thereof is between 1×10 4 and 3×10 5 dynes/cm 2 and the post-dosed modulus of elasticity thereof is between 1×10 4 and 2×10 6 dynes/cm 2 .
Claim 13
Dependent Claim
51 words
The composition of claim 1 wherein the composition is thixotropic, having a pre-dosed modulus of elasticity between 1×10 4 and 2×10 5 dynes/cm 2 and, after shaking, a pre-dosed viscosity between 1 and 5000 cps and having a post-dosed modulus of elasticity between 1×10 4 and 2×10 6 dynes/cm 2 .
Claim 14
Dependent Claim
10 words
The composition of claim 1 further comprising an ophthalmic agent.
Claim 15
Dependent Claim
12 words
The composition of claim 13 wherein the ophthalmic agent is para-amino clonidine.
Claim 16
Dependent Claim
14 words
The composition of claim 13 wherein the ophthalmic agent is a carbonic anhydrase inhibitor.
Claim 17
Dependent Claim
18 words
The composition of claim 15 wherein the carbonic anhydrase inhibitor is (+)-4-ethylamino-2,3-dihydro-4H-2-methylthieno-[3,2-e]1,2-thiazine-6-sulfonamide-1,1-dioxide or a pharmaceutically acceptable salt thereof.
Claim 18
Independent Claim
52 words
A method of delivering an ophthalmic agent to the eye which comprises topically administering a composition comprising: an ophthalmic agent, a gelling polysaccharide, and a finely-divided drug carrier substrate, wherein the concentration of said gelling polysaccharide allows the composition to be administrable as a drop which gels upon instillation to the eye.
Claim 19
Independent Claim
52 words
A method of delivering an ophthalmic agent to the eye which comprises topically administering a composition comprising: an ophthalmic agent, a gelling polysaccharide, and a finely-divided drug carrier substrate, wherein the concentration of said gelling polysaccharide allows the composition to be administrable as a drop which gels upon instillation to the eye.
Claim 20
Dependent Claim
16 words
The method of claim 17 wherein the finely-divided drug carrier substrate is an ion exchange resin.
Claim 21
Dependent Claim
31 words
The method of claim 17 wherein the gelling polysaccharide concentration is between 0.1% and 3.0% by weight/volume and the finely-divided drug carrier substrate concentration is between 0.05% and 10.0% by weight/volume.
Claim 22
Dependent Claim
25 words
The method of claim 17 wherein the gelling polysaccharide is selected from the group consisting of xanthan gum, locust bean gum, gellan gum, and carrageenan.
Claim 23
Dependent Claim
12 words
The method of claim 20 wherein the gelling polysaccharide is gellan gum.
Claim 24
Dependent Claim
23 words
The method of claim 20 wherein the gelling polysaccharide is a carrageenan having not more than 1.0 sulfate moiety per disaccharide repeating unit.
Claim 25
Dependent Claim
11 words
The method of claim 22 wherein said carrageenan is eucheuma carrageenan.
Claim 26
Dependent Claim
10 words
The method of claim 22 wherein said carrageenan is furcellaran.
Claim 27
Dependent Claim
12 words
The method of claim 17 wherein the ophthalmic agent is para-amino clonidine.
Claim 28
Dependent Claim
14 words
The method of claim 17 wherein the ophthalmic agent is a carbonic anhydrase inhibitor.
Claim 29
Dependent Claim
18 words
The method of claim 26 wherein the carbonic anhydrase inhibitor is (+)-4-ethylamino-2,3-dihydro-4H-2-methylthieno-[3,2-e]1,2-thiazine-6-sulfonamide-1,1-dioxide or a pharmaceutically acceptable salt thereof.
References Cited (Backward Citations)
US4014335A
Cited
US4136178A
Cited
US4136177A
Cited
US4136173A
Cited
US4505923A
Cited
US4931279A
Cited
US4861760A
Cited
US4911920A
Cited
US4983585A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-05-17 | 1996-11-16 | 1997-05-18 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-05-17 | 2000-11-16 | 2001-05-18 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-05-17 | 2004-11-16 | 2005-05-18 | $7700.00 | Window Closed / Lapsed |